Clinical Trial Update: Phase II Study of Subcutaneous Inj. Depot of Octreotide in Patients With Acromegaly and Neuroendocrine Tumours (NETs) [Phase 2]

View source ↗

Summary

Phase II study of a subcutaneous depot formulation of octreotide in acromegaly and neuroendocrine tumors has completed with posted results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acromegaly
• Neuroendocrine Tumors

Drugs mentioned

• OCTREOTIDE (OCTREOTIDE ACETATE)

Snippet

Sponsor: Camurus AB | Conditions: Acromegaly, Neuroendocrine Tumors | Phase 2 | Status: COMPLETED | Results posted: 2017-12-15